ROE % is calculated as Net Income attributable to Common Stockholders (Net Income minus dividends to participating security holders) divided by its average Total Stockholders Equity over a certain period of time. NovoCure's annualized net income attributable to common stockholders for the quarter that ended in Mar. 2022 was $-18.6 Mil. NovoCure's average Total Stockholders Equity over the quarter that ended in Mar. 2022 was $423.2 Mil. Therefore, NovoCure's annualized ROE % for the quarter that ended in Mar. 2022 was -4.39%.
The historical rank and industry rank for NovoCure's ROE % or its related term are showing as below:
NVCR'
s ROE % Range Over the Past 10 Years
Min: -67.07 Med: -48.19 Max: 5.71
Current: -14.51
During the past 9 years, NovoCure's highest ROE % was 5.71%. The lowest was -67.07%. And the median was -48.19%.
NVCR's ROE % is ranked worse than 62.99% of 789
companies
in the Medical Devices & Instruments industry
Industry Median: 1.74
vs NVCR: -14.51
NovoCure ROE % Historical Data
The historical data trend for NovoCure's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
NovoCure Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
ROE %
-48.19
-56.29
-4.38
5.71
-13.16
NovoCure Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
ROE %
-3.89
-15.22
-12.96
-25.70
-4.39
Competitive Comparison
For the Medical Instruments & Supplies subindustry, NovoCure's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovoCure ROE % Distribution
For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's ROE % distribution charts can be found below:
* The bar in red indicates where NovoCure's ROE % falls into.
NovoCure ROE % Calculation
NovoCure's annualized ROE % for the fiscal year that ended in Dec. 2021 is calculated as
ROE %
=
Net Income attributable to Common Stockholders (A: Dec. 2021 )
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income attributable to common stockholders of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income attributable to common stockholders data used here is four times the quarterly (Mar. 2022) net income attributable to common stockholders data.
ROE % is displayed in the 30-year financial page.
NovoCure (NAS:NVCR) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income attributable to common stockholders data used here is four times the quarterly (Mar. 2022) net income attributable to common stockholders data. The Revenue data used here is four times the quarterly (Mar. 2022) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
Be Aware
Net income attributable to common stockholders is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
NovoCure ROE % Related Terms
Thank you for viewing the detailed overview of NovoCure's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
3.77(4.99%) Volume: 261,460 1:45PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:NVCR has been successfully added to your 
